golimumab
Sign in to saveAlso known as CNTO-148
Golimumab, sold under the brand name Simponi, is a human monoclonal antibody which is used as an immunosuppressive medication. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. Golimumab is given via subcutaneous injection.
Key facts
- Drug.type
- mab
- Drug.image
- Golimumab 5yoy.png
- Drug.caption
- Cartoon representation of the antibody golimumab's variable fragment. The heavy and light chain fragments are coloured blue and yellow, respectively. From PDB entry
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- TNFα
- Drug.tradename
- Simponi, Simponi Aria
- Drug.MedlinePlus
- a610010
- Drug.DailyMedID
- Golimumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AB06
- Drug.biosimilars
- Gobivaz Gotenfia
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Research
1,941 papers- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.The lancet. Gastroenterology & hepatology · 2023
- Golimumab.mAbs · 2009
- Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.Gastroenterology · 2014
- Golimumab (anti-TNF monoclonal antibody): where we stand today.Human vaccines & immunotherapeutics · 2021
- Golimumab-Associated Glomerulonephritis.American journal of therapeutics · 2021
via PubMed
Wikidata facts
Show 3 more facts
- defined daily dose
- 1.66
- World Health Organisation international non-proprietary name
- golimumab
- Commons category
- Golimumab
via Wikidata · CC0
~5 min read
Article
9 sectionsContents
- Medical uses
- Adverse effects
- Development
- Society and culture
- Availability
- Biosimilars
- Research
- Rheumatoid arthritis
- References
Golimumab, sold under the brand name Simponi, is a human monoclonal antibody which is used as an immunosuppressive medication. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. Golimumab is given via subcutaneous injection.
Golimumab is a tumor necrosis factor alpha (TNF-a) inhibitor. Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF-a, which prevents the binding of TNF-a to its receptors. By blocking TNF-a, golimumab reduces the inflammation and other symptoms of the diseases it is used for.